The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, many therapeutic—as opposed to preventive—cancer vaccines have been in development, but none are approved. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.
Of Interest
Understanding Biomarkers in Early-Stage Melanoma
Hello, everybody. My name is Teresa Amaral, and today I’m here to talk to you about biomarkers. I would like to frame this in relation to the treatment of patients with melanoma, especially early-stage melanoma. Do we have any biomarkers that we could use in the early stage of melanoma?
NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.